


# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (KL-76)	EDRALBRUTINIB
PRONUNCIATION	ed ral bru' tin ib
THERAPEUTIC CLAIM	Treatment of B-cell malignancies and autoimmune diseases

## CHEMICAL NAMES

1. 7*H*-Pyrrolo[2,3-*d*]pyridazin-7-one, 4-amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3*R*)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]- (Source: CAS)
2. *R*)-4-amino-1-(1-(but-2-ynoyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-7*H*-pyrrolo[2,3-*d*]pyridazin-7-one (Source: ChemDraw)
3. 4-amino-1-[(3*R*)-1-(but-2-ynoyl)pyrrolidin-3-yl]-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-7*H*pyrrolo[2,3-*d*]pyridazin-7-one (Source: WHO pINN list 123)

## STRUCTURAL FORMULA



MOLECULAR FORMULA	C <sub>26</sub> H <sub>21</sub> F <sub>2</sub> N <sub>5</sub> O <sub>3</sub>
MOLECULAR WEIGHT	489.48
TRADEMARKS	None yet
SPONSOR	TG Therapeutics, Inc.
DESIGNATION CODES	TG-1701
CAS REGISTRY NUMBER	1858206-58-2
UNII	SG5I5QTR4E
WHO NUMBER	11426

## SCS